Key Abstracts in GU Cancers at ASCO24

How do we translate oncology breakthroughs into practice? In part one of a two-part miniseries, host Dr. Monty Pal and Dr. Atul Batra discuss the clinical realities, opportunities, and challenges of adapting ASCO26 Plenary findings into cancer care worldwide, using India's health ...  Show more

Dr. Monty Pal and Dr. Roselle De Guzman discuss key abstracts from the 2026 ASCO Breakthrough Meeting, including the real-world impact of liquid biopsies for early multi-cancer detection, AI applications in colorectal cancer screening, and how global advances in breast, esophagea ...  Show more

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ...  Show more

Neeraj Agarwal, MD, FASCO, describes the data from the TALAPRO-2 study on combination talazoparib and enzalutamide for metastatic castration-resistant prostate cancer as presented at the 2023 ASCO GU Cancers Symposium. Dr. Agarwal is a medical oncologist and Presidential Endow ...

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ...  Show more

The Uromigos met with Andrea Necchi, MD at the 2023 ASCO GU Cancers Symposium to discuss results of the phase 2 KEYNOTE-057 study on the use of pembrolizumab monotherapy for patients with high-risk non-muscle-invasive bladder cancer who are unresponsive to bacillus Calmette–Gu ...